Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Likar, R; Rupacher, E; Kager, H; Molnar, M; Pipam, W; Sittl, R.
[Efficacy of glycopyrronium bromide and scopolamine hydrobromide in patients with death rattle: a randomized controlled study].
Wien Klin Wochenschr. 2008; 120(21-22): 679-83. Doi: 10.1007/s00508-008-1094-2
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Likar Rudolf
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Death rattle is an extremely distressing symptom for the dying patient and for his environment. The aim of this study was to assess the efficacy of glycopyrronium bromide as compared with scopolamine hydrobromide in alleviating death rattle in terminal cancer patients with cognitive impairment. METHODS: In a randomized, controlled study design patients were allocated in two groups. Group A received scopolamine hydrobromide in a dose of 0.5 mg intravenously every 6 hours for a period of 12 hours, group B received glycopyrronium bromide 0.4 mg every 6 hours for a period of 12 hours. In addition, standardized sedatives were administered as required and the analgesic therapy continued either orally or, if necessary, subcutaneously or intravenously in equipotent doses. Every 2 hours death rattle was assessed and rated on a scale of 1 to 5 (1 = audible breathing noises, 5 = very severe rattling noises). In addition, restlessness and expressions of pain were assessed and rated on a scale of 1 to 3 (1 = mild, 2 = moderate, 3 = severe). RESULTS: 13 patients were included in the study, 7 patients were allocated to group A and 6 patients to group B. There were no significant differences in demographic data, age, weight and diagnosis distribution between the two groups. Group B demonstrated a significant reduction of death rattle in the first 12 hours (p = 0.029) in comparison to group A. There were no significant differences concerning the side effects (restlessness, expressions of pain) in both groups. CONCLUSION: Glycopyrronium bromide given in a dose of 0,4 mg every six hours demonstrated a significant reduction of death rattle compared to scopolamine hydrobromide. Concerning side effects (restlessness, expressions of pain) there was no difference between both substances.
Find related publications in this database (using NLM MeSH Indexing): Aged - administration & dosage; Bodily Secretions - drug effects; Double-Blind Method - administration & dosage; Female - administration & dosage; Glycopyrrolate - administration & dosage; Humans - administration & dosage; Male - administration & dosage; Muscarinic Antagonists - administration & dosage; Parasympatholytics - administration & dosage; Pilot Projects - administration & dosage; Placebo Effect - administration & dosage; Respiratory Sounds - drug effects; Scopolamine - administration & dosage; Terminal Care - methods; Treatment Outcome - administration & dosage
Find related publications in this database (Keywords): Glycopyrronium bromide; scopolamine hydrobromide; cancer patients; death rattle